Welcome to Crene Biotechnology!

+86-576-88205808

Product :

Daratumumab

Daratumumab 945721-28-8
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:Daratumumab Purity:95% min
CAS NO:945721-28-8 Solubility:Soluble in DMSO
Molecular Formula:C6466H9996N1724O2010S42 Package:Package according to customer requirements
Molecular Weight:145,391.67 g/mol Storage:Store at -20℃
Quality control
COA
Remarks

Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38,which multiple myeloma cells overexpress.Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. It was awarded orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

 

 

Related Prodcuts: 

Pembrolimumab; Secukinumab; Infliximab; Ramucirumab; Ipilimumab; Atezolizumab; Dulaglutide; Rituximab; Adalimumab; Denosumab; Cetuximab; Bevacizumab  

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China